- Reference code :
- wf296
- Published date :
-
17 November 1999
- Expired date :
-
04 April 2027
AstraZeneca today announced that the Tel Aviv District Court has held that AstraZeneca is entitled to an interlocutory injunction in Israel based on the formulation patent, to prevent Dexcel Ltd. from marketing a generic omeprazole product.
Omeprazole is the substance used in Losec®. The interlocutory injunction will not come into effect until the Supreme Court in Israel has considered Dexcel's application for leave to appeal.
Note to News Editors: |
|
|
|
|
|
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
